Page 2 - Interim Phase News Today

Next generation SupraAntigen liposomal vaccine platform augments immunization against pathological targets of Alzheimer's diseaseNew data on anti-phospho-Tau vaccines confirm safety, tolerability and immunogenicity

/PRNewswire/ -- FinancialNewsMedia.com News Commentary - Advanced pancreatic ductal adenocarcinoma (PDAC) remains a significant cause of mortality accounting...

Interim results from the phase 1/2 GOBLET study's pancreatic cancer cohort to be presented in a poster on November 11th and discussed during a key opinion leader webinar on November 14th at

/PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced the acceptance of two abstracts for poster presentations at the Society for...

SAN FRANCISCO--(BUSINESS WIRE)--May 31, 2022--

Interim Phase 4 Data Support TAKHZYRO® (lanadelumab) as an Effective Treatment to Reduce Attacks in Hereditary Angioedema PatientsFebruary 28, 2022Interim Real-World Data from Phase 4 EMPOWER Study Show Attack Rate Reduction and Improvement in Treatment Satisfaction and Other Patient-Reported Outcome Scores...

President, ECOWAS Commission, Mr. Jean-Claude Kassi Brou and the Director of the French Development Agency (AFD) in Nigeria, Mr. Xavier Muron have signed a grant agreement for a complementary funding

The Central government is examining the recommendation of the Subject Expert Committee (SEC) regarding the grant of market authorization of Covaxin for the age group of 2 to 18 years for restricted use in an emergency situation subject to various conditions, Ministry of Health and Family Welfare (MoHF) told Rajya Sabha on Tuesday.

The Interim Phase II, III clinical trial data of COVAXIN on Healthy Volunteers aged 2 to 18 years submitted by Bharat Biotech was deliberated in the meeting of the Subject Expert Committee (SEC) on August 28 and October 11, informed Ministry of Health and Family Welfare.

The Central government is examining the recommendation to grant market authorization to Covaxin for the age group of 2 to 18 years.